The Method
In order to test the aims/goals of STATIC, we are testing two different ways of taking BTK inhibitors (a type of CLL treatment), either ibrutinib or acalabrutinib.
Participants of the trial will be randomly assigned to one of two treatment groups:
- Pausing Treatment
Participants in this group take a scheduled break from treatment (ibrutinib or acalabrutinib), and only restart if their CLL gets worse. If restarting treatment controls the CLL again, participants will take another break from treatment. - Continuous Treatment
Participants in this group will take either ibrutinib or acalabrutinib every day. Participants will continue treatment without a break as long as they are benefitting from it.